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Abstract Various studies have been published in Italy
regarding the different BRCA1 mutations, but only the
BRCA1-5083del19 mutation is recurrent and specific to
individuals of Italian descent with a founder effect on the
Calabrian population. In our previous study, BRCA1-
5083del19 mutation carriers were found in four index cases
of 106 Sicilian patients selected for familial and/or
hereditary breast/ovarian cancers. The high frequency rate
of this mutation identified in the Sicilian population led us
to perform haplotype analysis in all family carriers. Five
highly polymorphic microsatellite markers were used
(D17S1320, D17S932, D17S1323, D17S1326, D17S1325)
to establish whether or not all these families had a common
ancestor. This analysis showed that all mutation carriers of
these families had a common allele. None of the non-
carriers of the mutation or of the 50 healthy Sicilian con-
trols showed this haplotype. This allelotype analysis
highlighted the presence of a common allele (ancestor),
thus suggesting the presence of a founder effect in the
Sicilian population. Our results are in contrast with other
studies but only the allelotype analysis of all the BRCA1-
5083del19 mutation carriers of two neighboring regions of
the south of Italy (Calabria and Sicily) will make it possible
to identify the real ancestor of this mutation.
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Introduction
From 5–10% of breast and ovarian cancers are hereditary;
most of them can be attributed to mutations occurring in
genes located in various chromosomes. BRCA1 and BRCA2
are known as susceptibility genes and appear to be involved
in 30–45% of the cases which map in chromosomes 17q21
and 13q12–13 respectively [1–3]. The frequency and type
of mutations in these genes vary according to the geo-
graphical area and ethnic group involved. Many such
alterations may often be recurrent and have been identified
in isolated populations as the results of a founder effect.
Founder mutations in BRCA1 and BRCA2 genes have
been described in several western European countries, but
the most evident and restricted forms are those observed in
the Icelandic and Ashkenazi Jewish populations [4–6].
BRCA1-185delAG is present in 1% of the Ashkenazi Jews
and in 20% of Ashkenazi women affected by breast cancer
before the age of 42 years [7]. A further BRCA1 founder
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mutation (5832insC) is found in 0.11% of the general
population [8]. This mutation is frequently present in Jews
and has moreover been identified in Poland, Lithuania,
Hungary, Russia and in a large number of European coun-
tries [9–14]. The haplotype analysis of the mutation carriers
show that such subjects have a common ancestor.
In Italy, different studies have been published regarding
the different BRCA1 mutations, but only the BRCA1-
5083del19 mutation is recurrent and specific to individuals
of Italian descent.
Baudi et al. described this mutation as a founder mutation
specific to the Italian population, but all the patients selected
for their family history and as carriers of the mutation were of
Calabrian origin. The haplotype analysis in these families
shows that they have a common allele [15].
In a Canadian study involving 116 women with primary
breast or ovarian cancer who had at least one Italian
ancestor, the presence of BRCA1-5083del19 was observed
in 5 families, only 3 of which quite certainly of Calabrian
origin [16].
A knowledge of the nature and frequency of population-
specific mutations in susceptibility genes is an important
step towards the development of a valid diagnostic
approach to DNA analysis in particular ethnic groups [17].
In our study BRCA1-5083del19 mutation was found in
4% of 106 patients selected for familial and/or hereditary
breast/ovarian cancers and all families confirmed their
Sicilian origin [18].
The high frequency rate of this mutation found in the
Sicilian population analyzed led us to perform haplotype
analysis with five highly polymorphic microsatellite
markers to establish whether or not all these families had a
common ancestor.
Patients and methods
Patients
Four unrelated families with hereditary/familial breast and
ovarian cancer were recruited after interview at the
‘‘Regional Reference Center for the Characterization and
Genetic Screening of Hereditary Tumors’’ at the University
of Palermo. All members declared that they originated
from the Southern Italian region of Sicily.
Blood samples were obtained from four affected pro-
bands and from unaffected family members after obtaining
written informed consent. All relatives underwent genetic
counseling, conducted by an oncologist, a geneticist and
a psychologist and were asked to provide information
regarding their personal and familial history so that we were
able to evaluate risk assessment and their genealogical tree.
The latter was updated every year and investigated for at
least three generations in order to identify patients with
breast/ovarian cancer or other types of tumors and to eval-
uate the presence within the family of neoplasias related to
BRCA1-associated tumors. All cancer diagnoses were con-
firmed by the pathologist’s reports.
Twelve members of four families were enrolled for the
study. Blood samples obtained from 50 healthy Sicilians
served as controls; informed consent was obtained from all
subjects before the collection of samples. All the material
regarding each individual case (a personal data chart,
interviews, blood samples) was filed under an individual
personal code in order to respect the patient’s privacy.
Mutation detection
Genomic DNA was extracted from whole peripheral blood
according to the instructions contained in the QIAamp
Blood Kit (Qiagen, Hilden, Germany). Direct sequencing
of the PCR product of exon 16 of the BRCA1 gene was
performed using a BigDye Terminator v3.1 and then
sequencing by ABI PRISM 3100 Avant Genetic Analyzer
(Applied Biosystems, Foster City, CA) as described pre-
viously [18]. Each genetic variant was confirmed by direct
sequencing analysis on two independent blood samples.
Haplotype analysis
The BRCA1 haplotype was analyzed by using 5 microsat-
ellite repeat markers located on chromosome 17q within
or near BRCA1. From centromere to telomere, the order
reported in the NCBI Data Base (http://www.ncbi.nlm.
nih.gov) is as follows: D17S1320, D17S932, D17S1323,
D17S1326, D17S1325 [19]. Primer sequences to amplify
these markers retrieved on-line from the NCBI Data Base.
Standard PCR protocol were used. The amplified products
were visualized by microsatellite analysis with an auto-
mated apparatus (ABI Prism 3100 Avant, Applied
Biosystems, USA).
The microsatellite repeat markers have been chosen so
that two of them, D17S932 and D17S1323, are in inside the
gene BRCA1, the first in intron 12 and the other in intron 19.
The locus D17S1320 is at 500 kb upstream from the
gene, while the other two D17S1326 and D17S1325 are
downstream, and are at 195 kb and 400 kb from D17S1323
respectively.
Results
Of four 5083del19 mutation carriers probands (5Si, 13Si,
45Si, 55Si), three had a strong family history. Only
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proband 45Si had been affected by early-onset breast
cancer (at age 39), but no other member of her family had
been affected by a tumor; furthermore, no other family
member consented to be interviewed and undergo onco-
genetic counseling. Twelve members of the four families
were thus recruited during genetic counseling.
The proband of the 5Si family was a multiparous non-
Ashkenazi woman with bilateral breast cancer (43, 47). A
maternal aunt who had developed breast cancer at age 50
and died at the age of 60. Both her brother and her daughter
were healthy carriers of the BRCA1-5083del19 mutation.
The 13Si index-case was a multiparous non-Ashkenazi
woman with bilateral breast cancer developing at ages 70
and 93. Two of her daughters had developed ovarian cancer
(46 and 50) and one of her granddaughters had developed
breast cancer at 32 age; only one other daughter decided to
undergo genetic testing and was found to be a healthy
mutation carrier.
The proband of the 55Si family was a multiparous non-
Ashkenazi woman with bilateral breast cancer (42, 70).
Both her sons were healthy carriers, and her daughter, who
had died of breast cancer at the age of 32, must certainly
have been a carrier, since both her children were found to
be healthy carriers. This woman had a sister with breast
cancer at 50 age and a nephew with ovarian cancer at
45 age.
Twelve members of four families were typed with five
microsatellite markers within or flanking the BRCA1 gene.
All the cases with the BRCA1-5083del19 mutation shared
a common haplotype at loci D17S1320, D17S932, D17S1323,
D17S1326, D17S1325, respectively. The genealogical tree of
the 5Si family shows the segregation of the allele associated
with the BRCA1-5083del19 mutation (Fig. 1).
Haplotype analysis for non-carriers of the mutation
showed that none of these and none of the 50 healthy
Sicilian controls had this haplotype associated with the
BRCA1-5083del19 mutation.
Allelotype analysis highlighted the presence of a com-
mon allele in the affected individuals and healthy carriers,
therefore suggesting the presence of a founder effect in
Sicilian families.
Discussion
The proportion of families at high-risk due to BRCA1 gene
germline mutations varies widely among populations. In
some groups a wide spectrum of different mutations are
present, whereas in others specific mutations have been
reported with high frequency as the result of a founder effect.
The comparison of haplotypes between families with the
same mutation can distinguish whether high-frequency
alleles derive from an older or more recent single
mutational event or whether they have arisen indepen-
dently more than once.
The first example of BRCA1 founder mutation in the
Italian population was described by Baudi et al. in 2000.
All the families with BRCA1-5083del19 mutation origi-
nated from Calabria and haplotype analysis performed on
the probands and on the healthy family carriers showed a
common allele. This indicated a founder effect, in con-
cordance with the genetic background of the Calabrian
population, which is homogeneous and associated with
negligible immigratory phenomena [15].
In 2004, the ‘‘Italian Consortium of Hereditary Breast
and Ovarian Cancer’’ established that the prevalence of
BRCA1/2 mutations in 1758 Italian families was 23% and
only a few of these mutations proved to be recurrent in
particular geographical areas, among which BRCA1-
5083del19, considered as the Calabrian founder mutation
[20].
A North American study performed on 116 women of
Italian origin with primary breast or ovarian cancer showed
this mutation in 5 of the families involved, three of which
of Calabrian origin [16].
These data highlighted that this is a founder mutation
most probably originating in Calabria.
In 2006, we published the first study regarding BRCA1
gene molecular screening in Sicilian patients affected by
breast and/or ovarian tumors and identified 4 families
carrying this mutation. Three index cases had bilateral
breast cancer and within their families there were members
affected by both breast and ovarian cancers, as already
Fig. 1 Abbreviated pedigree of one of four Sicilian families that
result BRCA1-5083del19 mutation carriers. The index case is
indicated by an arrow. Each member show the result of haplotype
analysis performed with five microsatellite markers
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found in the other Italian families who were BRCA1-
5083del19 mutation carriers [18].
Our results were not included in those of the Italian
Consortium, since we studied the Sicilian population only
subsequent to its publication. All our probands declared
that they were of Sicilian origin. Allelotype analysis with 5
microsatellite repeat markers within or near BRCA1 high-
lighted the presence of a common allele in the four affected
individuals and eight healthy carriers, therefore suggesting
the presence of a common ancestor.
Several other recurrent mutations have been identified in
other limited areas of Italy, but only genetic screening
performed on a larger number of cases within the various
regions of the country will make it possible to reach more
definite conclusions regarding the presence of this founder
effect.
The identification of the ethnic group of families
undergoing genetic counseling enables the geneticist and
oncologist to make more specific choices, helping to sim-
plify the clinical approach to genetic testing performed on
members of high-risk families.
In conclusion, only a haplotype analysis using the same
microsatellite repeat markers in all BRCA1-5083del19
mutation carriers of Italian families will make it possible to
understand if all these families originating from two
neighboring regions of the south of Italy (Calabria and
Sicily) have a common ancestor.
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